Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(4):725-738. Published online March 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0015

View: 5057 Download: 252 Web of Science: 7 Crossref: 13

The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology

Youngseok Lee, Jong-Hoon Kim

Clin Mol Hepatol. 2022;28(4):706-724. Published online March 2, 2022

DOI: https://doi.org/10.3350/cmh.2021.0390

View: 12763 Download: 271 Web of Science: 9 Crossref: 12

Guideline

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clin Mol Hepatol. 2022;28(4):583-705. Published online October 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0294

View: 11916 Download: 716 Web of Science: 107 Crossref: 113

Snapshot

Microbiome and metabolomics in alcoholic liver disease

Raja Ganesan, Ki Tae Suk

Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0171

View: 4889 Download: 157 Web of Science: 5 Crossref: 6

Letter to the Editor

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura

Clin Mol Hepatol. 2022;28(3):575-579. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0047

View: 3405 Download: 204 Web of Science: 6 Crossref: 6

Original Article

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah

Clin Mol Hepatol. 2022;28(3):565-574. Published online May 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0096

View: 6898 Download: 199 Web of Science: 45 Crossref: 48

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients

Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, Xianhua Mao, Ruiqi R Zhang, Kwok Hung Chan, Ivan FN Hung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):553-564. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0082

View: 3514 Download: 90 Web of Science: 11 Crossref: 12

Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study

Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi

Clin Mol Hepatol. 2022;28(3):540-552. Published online May 6, 2022

DOI: https://doi.org/10.3350/cmh.2021.0169

View: 4772 Download: 120 Web of Science: 3 Crossref: 5

Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4

Yang Liu, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, Harouna Aboubacar, Junhui Li, Tao Shan, Jixin Wang, Gang Cao

Clin Mol Hepatol. 2022;28(3):522-539. Published online May 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0039

View: 5215 Download: 186 Web of Science: 16 Crossref: 18

Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults

Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(3):510-521. Published online March 17, 2022

DOI: https://doi.org/10.3350/cmh.2021.0332

View: 6516 Download: 291 Web of Science: 30 Crossref: 26

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim

Clin Mol Hepatol. 2022;28(3):497-509. Published online April 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0019

View: 6002 Download: 170 Web of Science: 7 Crossref: 5

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals

Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng

Clin Mol Hepatol. 2022;28(3):483-496. Published online March 2, 2022

DOI: https://doi.org/10.3350/cmh.2021.0406

View: 7547 Download: 271 Web of Science: 39 Crossref: 49

Editorial

Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Byoung Seok Ye

Clin Mol Hepatol. 2022;28(3):481-482. Published online May 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0097

View: 2875 Download: 75 Web of Science: 1 Crossref: 2

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 3203 Download: 91

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0155

View: 3645 Download: 99 Web of Science: 2 Crossref: 2

Review

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim

Clin Mol Hepatol. 2022;28(3):425-472. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0186

View: 7582 Download: 372 Web of Science: 12 Crossref: 13

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

View: 8592 Download: 628 Web of Science: 35 Crossref: 40

Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance

Mina Komuta

Clin Mol Hepatol. 2022;28(3):396-407. Published online January 14, 2022

DOI: https://doi.org/10.3350/cmh.2021.0287

View: 6103 Download: 347 Web of Science: 15 Crossref: 16

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

Myung Ji Goh, Dong Hyun Sinn

Clin Mol Hepatol. 2022;28(3):380-395. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0366

View: 4991 Download: 179 Web of Science: 11 Crossref: 10

Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound

Junghoan Park, Jeong Min Lee, Tae-Hyung Kim, Jeong Hee Yoon

Clin Mol Hepatol. 2022;28(3):362-379. Published online December 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0361

View: 6120 Download: 232 Web of Science: 16 Crossref: 18

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee

Clin Mol Hepatol. 2022;28(3):351-361. Published online November 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0281

View: 5264 Download: 256 Web of Science: 15 Crossref: 15

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350. Published online October 19, 2021

DOI: https://doi.org/10.3350/cmh.2021.0308

View: 17002 Download: 363 Web of Science: 22 Crossref: 24

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 10979 Download: 604 Web of Science: 41 Crossref: 49

Snapshot

Acute on chronic liver failure in cirrhosis

Marta Tonon, Salvatore Piano

Clin Mol Hepatol. 2022;28(2):273-275. Published online February 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0036

View: 5837 Download: 228 Web of Science: 1 Crossref: 1

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 5108 Download: 335 Web of Science: 7 Crossref: 8

Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Jihyun An, Ju Hyun Shim

Clin Mol Hepatol. 2022;28(2):267-268. Published online January 18, 2022

DOI: https://doi.org/10.3350/cmh.2022.0013

View: 2973 Download: 56

Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei

Clin Mol Hepatol. 2022;28(2):265-266. Published online January 4, 2022

DOI: https://doi.org/10.3350/cmh.2021.0412

View: 6664 Download: 41 Web of Science: 1 Crossref: 1

Original Article

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 5400 Download: 287 Web of Science: 23 Crossref: 24

Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area

Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho

Clin Mol Hepatol. 2022;28(2):242-253. Published online February 7, 2022

DOI: https://doi.org/10.3350/cmh.2021.0355

View: 5462 Download: 124 Web of Science: 14 Crossref: 12

Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats

Ki Tae Yoon, Hongqun Liu, Jing Zhang, Sojung Han, Samuel S. Lee

Clin Mol Hepatol. 2022;28(2):232-241. Published online January 5, 2022

DOI: https://doi.org/10.3350/cmh.2021.0141

View: 5131 Download: 115 Web of Science: 7 Crossref: 7

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5405	MAFLD: How is it different from NAFLD?
Viewed By 5214	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5094	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4725	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Article category